# A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis

> **NCT07250646** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Aspera Biomedicines, Inc.** · enrollment: 28 (estimated)

## Conditions studied

- Secondary AML
- Myelofibrosis

## Interventions

- **DRUG:** rebecsinib

## Key facts

- **NCT ID:** NCT07250646
- **Lead sponsor:** Aspera Biomedicines, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2027-10
- **Final completion:** 2028-04
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-01-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07250646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07250646, "A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07250646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*